AbbVie Neuroscience Revenue Rises 19.4% to $3.39B in Q3
AbbVie reported third-quarter global neuroscience portfolio revenue of $3.39 billion, up 19.4%.
Related stories
Imperial Oil earnings above expectations at 5.11 CAD
Imperial Oil (IMO) released earnings per share at 5.11 CAD, compared to market expectations of 4.03 CAD.
H impact | EARNINGS | Oct 30, 2026, 02:47 PM UTC
Canadian National Railway earnings above expectations at 2.16 CAD
Canadian National Railway (CNR) released earnings per share at 2.16 CAD, compared to market expectations of 2.02 CAD.
H impact | EARNINGS | Oct 30, 2026, 02:47 PM UTC
Syngenta Group Revenue Falls as Heatwave Hurts Sales
Syngenta said a European summer heatwave reduced demand for its crop-protection products, while cash-strapped farmers bought fewer new seeds.
M impact | EARNINGS | Oct 30, 2026, 02:45 PM UTC
Illumina Falls After Missing Third-Quarter Revenue Targets
Illumina shares fell after the company missed its third-quarter revenue targets.
M impact | EARNINGS | Oct 30, 2026, 02:44 PM UTC
CBOE Global Markets Reports Quarter-End Results
CBOE Global Markets reported results for the quarter ended September 30. The supplied text provides no figures.
M impact | EARNINGS | Oct 30, 2026, 02:39 PM UTC
Regeneron Hits 52-Week Highs as Q3 Adjusted EPS Jumps 70%
Regeneron’s Q3 adjusted EPS surged 70% to $20.07, topping estimates, as Dupixent growth and improved collaboration economics supported results.
M impact | EARNINGS | Oct 30, 2026, 02:35 PM UTC